设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至[email protected]

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑(兼编辑部主任):

杨秋
副总编辑:魏永祥、张运、

罗毅、谭学瑞、唐来坤、

王喜艳

编辑部副主任:杨水霞
邮发代号:80-528
定价:18.00元
全年:216.00元
Email:[email protected]
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2019 年第 5 期 第 14 卷

二甲双胍联合西格列汀或瑞格列奈治疗肥胖2型糖尿病患者的效果比较

Efficacies of metformin combined with sitagliptin or repaglinide in treatment of obese patients with type 2 diabetes mellitus

作者:吴金婵陈娟冯光球

英文作者:

单位:570311海口,海南省人民医院医疗保健中心四病区

英文单位:

关键词:2型糖尿病;西格列汀;瑞格列奈;肥胖

英文关键词:

  • 摘要:
  • 【摘要】

    【摘要】目的    探讨二甲双胍联合西格列汀或瑞格列奈治疗肥胖2型糖尿病患者的效果。方法    选取2017年1月至2018年4月在海南省人民医院就诊的肥胖2型糖尿病患者100例。采取随机数字表法分为对照组和观察组,各50例。对照组在常规治疗基础上给予二甲双胍联合瑞格列奈片口服,观察组在常规治疗基础上给予二甲双胍联合西格列汀片口服。比较2组患者治疗前和治疗3个月后体重指数、血糖、胰岛素抵抗指数和血脂以及血清丝氨酸蛋白酶抑制物(vaspin)、瘦素、脂联素水平和不良反应的发生率。结果    治疗前,2组患者各观察指标水平比较差异均无统计学意义(均P>0.05)。治疗3个月后,2组患者体重指数、空腹血糖、餐后2 h血糖、糖化血红蛋白、胰岛素抵抗指数、三酰甘油、总胆固醇、低密度脂蛋白胆固醇、vaspin、瘦素水平均低于治疗前,高密度脂蛋白胆固醇、脂联素水平均高于治疗前,且观察组体重指数、总胆固醇、低密度脂蛋白胆固醇、vaspin、瘦素水平低于对照组[(23.0±2.7)kg/m2比(25.7±2.8)kg/m2,(3.1±0.4)mmol/L比(4.2±0.5)mmol/L,(2.21±0.26)mmol/L比(2.71±0.34)mmol/L,(1.31±0.15)μg/L比(2.20±0.24)μg/L,(5.5±0.6)μg/L比(7.2±0.8)μg/L],高密度脂蛋白胆固醇、脂联素水平高于对照组[(1.52±0.19)mmol/L比(1.27±0.18)mmol/L,(8.2±0.9)mg/L比(4.1±0.4)mg/L],差异均有统计学意义(均P<0.01)。2组患者治疗期间不良反应发生率比较差异无统计学意义(P>0.05)。结论    在服用二甲双胍基础上口服西格列汀或瑞格列奈均能使血糖达标,但西格列汀在降低体质量、血脂方面效果更佳,且可进一步调节患者血清vaspin、瘦素、脂联素水平。

  • 【Abstract】Objective    To investigate the efficacies of metformin combined with sitagliptin or repaglinide in treating obese patients with type 2 diabetes mellitus. Methods    From January 2017 to April 2018, 100 obese patients with type 2 diabetes in Hainan General Hospital were randomly divided into control group and observation group, with 50 cases in each group. The control group took metformin plus repaglinide on the basis of routine treatment. The observation group took metformin plus sitagliptin on the basis of routine treatment. Body mass index, blood glucose, insulin resistance, blood lipids, serum serine protease inhibitor(vaspin), leptin and adiponectin were detected before and 3 months after treatment. Adverse reactions were observed. Results    Before treatment, the measurements were similar between groups(P>0.05). After 3 months of treatment, body mass index, fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin, insulin resistance index, triglyceride, total cholesterol, low-density lipoprotein cholesterol, vaspin and leptin levels significantly decreased and high-density lipoprotein cholesterol and adiponectin levels significantly increased compared to those before treatment; body mass index, total cholesterol, low-density lipoprotein cholesterol, vaspin and leptin levels in observation group were lower than those in control group[(23.0±2.7)kg/mg2 vs (25.7±2.8)kg/mg2, (3.1±0.4)mmol/L vs (4.2±0.5)mmol/L, (2.21±0.26)mmol/L vs (2.71±0.34)mmol/L, (1.31±0.15)μg/L vs (2.20±0.24)μg/L, (5.5±0.6)μg/L vs (7.2±0.8)μg/L]; high-density lipoprotein cholesterol and adiponectin levels in observation group were higher than those in control group[(1.52±0.19)mmol/L vs (1.27±0.18)mmol/L, (8.2±0.9)mg/L vs (4.1±0.4)mg/L](all P<0.01). There was no significant difference of the incidence of adverse reactions between groups(P>0.05). Conclusions    Metformin plus sitagliptin or repaglinide can effectively regulate blood glucose. Sitagliptin is effective in reducing body mass and blood lipids, regulating serum vaspin, leptin and adiponectin.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: [email protected]
网址:www.chinamedicinej.com 京ICP备10041176号-1
本系统由北京博思汇文数字科技有限公司设计开发 技术服务电话:400-921-9838
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱[email protected]







安卓


苹果

关闭